01 7Rupafin
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 73
2019 Revenue in Millions : 52
Growth (%) : 39
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 75
2020 Revenue in Millions : 72
Growth (%) : 13
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 74
2021 Revenue in Millions : 74
Growth (%) : 0
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 65
2022 Revenue in Millions : 74
Growth (%) : -2
Main Therapeutic Indication : Immunology
Currency : USD
2024 Revenue in Millions : 61
2023 Revenue in Millions : 73
Growth (%) : -15
Main Therapeutic Indication : Anti-Allergic
Currency : USD
2018 Revenue in Millions : 9
2017 Revenue in Millions : 0
Growth (%) : NA
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 60
2018 Revenue in Millions : 9
Growth (%) : 550
